Biomarkers in Parkinsonian Syndromes (NCT06501469)

Biomarkers for Parkinsonian Syndromes NCT06501469

ClinicalTrials.gov Identifier: [NCT06501469](https://clinicaltrials.gov/study/NCT06501469)

Overview

Biomarkers for Parkinsonian Syndromes NCT06501469

ClinicalTrials.gov Identifier: [NCT06501469](https://clinicaltrials.gov/study/NCT06501469)

Overview

Biomarkers in Parkinsonian Syndromes (NCT06501469) is a prospective observational study designed to identify and validate biomarkers for parkinsonian syndromes, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS)[@clinicaltrialsgov2026]. This study addresses a critical unmet need in neurodegenerative disease research: the lack of reliable biomarker-based diagnostic tools that can distinguish between these overlapping syndromes at early disease stages.

Study Information

| Field | Value |
|-----------|-----------|
| NCT Number | NCT06501469 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Follow-up Duration | At least 5 years |
| Primary Outcome | Establishment of clinical diagnosis |
| Secondary Outcomes | Biomarker validation, disease progression tracking |
| Enrollment Target | 500-1000 participants |
| Age Range | 40-85 years |
| Study Sites | Multiple academic medical centers |

Scientific Rationale

The Diagnostic Challenge

Early accurate diagnosis of parkinsonian syndromes remains a significant challenge in neurology. While clinical criteria exist for PSP, MSA, and CBS, diagnostic accuracy in early disease stages is limited to approximately 50-70%[@2024_ninds_psp_criteria]. The key challenges include:

This study aims to address these gaps by systematically collecting:

• Imaging biomarkers (MRI, PET, SPECT)
• Wet biomarkers (blood, CSF)
• Clinical data and longitudinal assessments
• Digital biomarkers (wearable sensor data)

Disease Background

Progressive Supranuclear Palsy

PSP is a 4R-tauopathy characterized by accumulation of abnormal tau protein in the basal ganglia, brainstem, and cerebellar structures. The classic Richardson's phenotype presents with vertical supranuclear gaze palsy, early falls, and frontal cognitive impairment. However, multiple variants are recognized:

• PSP-Parkinsonism (PSP-P): Predominant parkinsonian features, slower progression
• PSP-Pure Akinesia with Gait Freezing (PAGF): Early gait freezing, minimal ocular findings
• PSP-Cerebellar (PSP-C): Prominent cerebellar ataxia
• Frontal Variant PSP: Predominant behavioral and cognitive symptoms

Multiple System Atrophy

MSA is a synucleinopathy divided into two subtypes:

• MSA-P: Predominant parkinsonian features with autonomic failure
• MSA-C: Predominant cerebellar ataxia with autonomic failure

Corticobasal Syndrome

CBS is a clinically heterogeneous syndrome typically characterized by:

• Asymmetric parkinsonism
• Cortical sensory loss
• Alien limb phenomena
• Apraxia
• Cognitive decline

Study Design

Inclusion Criteria

The study recruits patients with parkinsonian syndromes at early disease stages who will be followed prospectively until a definitive clinical diagnosis is established. Key eligibility includes:

• Age 40-85 years
• Clinical diagnosis or suspicion of PSP, MSA, or CBS
• Disease duration <5 years
• Ability to undergo repeated MRI and biomarker collection
• Informed consent

Data Collection Timeline

| Visit | Timepoint | Assessments |
|-----------|---------------|-----------------|
| Baseline | Day 0 | Full biomarker panel, clinical assessments |
| Year 1 | 12 months | Repeat biomarker panel, clinical scores |
| Year 2 | 24 months | Repeat biomarker panel, clinical scores |
| Year 3 | 36 months | Repeat biomarker panel, clinical scores |
| Year 5 | 60 months | Final assessment, definitive diagnosis |

Biomarker Types Collected

| Biomarker Type | Examples | Clinical Utility |
|-------------------|--------------|---------------------|
| Neuroimaging | MRI, PET, SPECT | Structural/functional changes |
| Fluid biomarkers | CSF, blood, serum | Protein signatures, neurodegeneration markers |
| Clinical scales | Motor assessments, cognitive tests | Phenotypic characterization |
| Digital biomarkers | Wearable sensor data | Real-world function monitoring |

Neuroimaging Biomarkers

Magnetic Resonance Imaging (MRI)

Structural MRI Markers

MRI plays a crucial role in differentiating parkinsonian syndromes through characteristic atrophy patterns:

PSP Imaging hallmarks:

• Midbrain atrophy: "Hummingbird sign" on midsagittal MRI
• Superior cerebellar peduncle (SCP) atrophy: Contributing to the "Mickey Mouse sign"
• Frontal lobe atrophy: Particularly in dorsal prefrontal regions
• Third ventricle enlargement: Reflecting thalamic and hypothalamic involvement
• Pontine tegmental atrophy

• Hot cross bun sign: Pontine crossing fiber degeneration on T2-weighted MRI
• Cerebellar atrophy: Especially in the vermis for MSA-C
• Putaminal atrophy and hypointensity: With peripheral rim hyperintensity
• Brainstem atrophy: Less pronounced than in PSP

• Asymmetric cortical atrophy: Parietal and frontal regions
• Central atrophy: Including the substantia nigra and red nucleus
• Corpus callosum thinning: Particularly in the body region

Advanced MRI Techniques

• Diffusion Tensor Imaging (DTI): Measures white matter integrity, showing distinct patterns of fractional anisotropy reduction
• Susceptibility-Weighted Imaging (SWI): Detects iron deposition in basal ganglia
• Quantitative Susceptibility Mapping (QSM): Quantifies iron accumulation
• Magnetization Transfer Imaging: Sensitive to myelin changes

Positron Emission Tomography (PET)

Tau PET Imaging

Tau PET tracers have shown differential binding patterns across parkinsonian syndromes:

• PI-2620: High affinity for 3R/4R tau, shows elevated binding in PSP basal ganglia
• PM-PBB3: Binds to both 3R/4R tau and 2N tau isoforms
• FTP (Flortaucipir): Originally developed for AD tau, shows binding in PSP

• PSP: Elevated binding in basal ganglia, midbrain, dentate nucleus
• MSA: Generally lower tau binding, more focal patterns
• CBS: Variable patterns depending on underlying pathology

Amyloid PET

• Florbetapir (18F-AV-45): Rules in/out AD pathology
• Helps determine whether CBS cases have co-occurring AD pathology

Dopaminergic Imaging

• DAT SPECT/PET: Measures dopamine transporter availability
• Reduced uptake in both PSP and MSA
• More severe reduction in MSA compared to PSP
• Helps differentiate from essential tremor and psychogenic parkinsonism
• FP-CIT (DaTscan): FDA-approved for differentiating degenerative parkinsonism

Metabolic PET (FDG)

• Characteristic hypometabolism patterns:
• PSP: Midline frontal cortex, brainstem, cerebellar vermis
• MSA: Cerebellar, brainstem, basal ganglia
• CBS: Asymmetric parietal-frontal cortex

Single Photon Emission Computed Tomography (SPECT)

• 123I-Ioflupane (DaTscan): DAT imaging for parkinsonism differentiation
• 123I-MIBG: Cardiac sympathetic imaging
• Reduced uptake in PD and MSA (postganglionic involvement)
• Preserved uptake in PSP (preganglionic)

Fluid Biomarkers

Cerebrospinal Fluid (CSF) Biomarkers

Neurodegeneration Markers

Neurofilament Light Chain (NfL)

NfL is a sensitive marker of axonal damage across neurodegenerative diseases. Studies have shown[@neurofilament_biomarkers]:

• Elevated CSF NfL in all parkinsonian syndromes compared to healthy controls
• Highest levels in MSA: Likely reflecting greater white matter involvement
• Intermediate levels in PSP: Correlating with disease severity
• Lower levels in CBS: Unless there is concurrent AD pathology

Tau Proteins

• Total tau (t-tau): Moderately elevated in PSP and CBS
• Phosphorylated tau (p-tau181, p-tau217):
• Elevated in cases with AD co-pathology
• May help predict CBS cases with AD pathology

Alpha-Synuclein

• Total alpha-synuclein: Reduced in MSA compared to PD
• Phosphorylated alpha-synuclein (pSer129): Elevated in all synucleinopathies
• Seed Amplification Assays (SAA):
• Differential detection patterns between PD, MSA, and DLB
• Sensitivity and specificity approaching 90% in research settings

Other CSF Markers

• β-amyloid 1-42: Reduced in cases with AD co-pathology
• YKL-40 (chitinase-3-like protein 1): Microglial activation marker
• Neurogranin: Synaptic degeneration marker
• VILIP-1: Neuronal injury marker

Blood Biomarkers

Plasma/Serum Neurofilament Light Chain

• Strong correlation with CSF NfL levels
• More accessible for clinical practice
• Currently under validation for clinical use

Emerging Blood Biomarkers

• p-tau181, p-tau217: AD-specific, may help in CBS workup
• GFAP (Glial Fibrillary Acidic Protein): Astrocyte activation
• Neuronal Pentraxin 2 (NPTX2): Synaptic marker
• Small extracellular vesicles (sEVs): Contain CNS-derived proteins

Clinical Assessment Tools

Motor Assessments

• Unified Parkinson's Disease Rating Scale (UPDRS): Part III (motor examination)
• MDS-UPDRS: Updated version with enhanced sensitivity
• PSP Rating Scale (PSPRS): Specific for PSP severity
• Scale for Outcomes for Progressive Supranuclear Palsy (SPSMA): Validated for PSP
• International Cooperative Ataxia Rating Scale (ICARS): Cerebellar assessment
• Timed Up and Go (TUG): Gait and mobility
• Pull Test: Postural stability

Cognitive Assessments

• Montreal Cognitive Assessment (MoCA): Screening
• Frontal Assessment Battery (FAB): Frontal/executive function
• Trail Making Test A/B: Processing speed, executive function
• Stroop Test: Response inhibition
• Wisconsin Card Sorting Test: Cognitive flexibility

Autonomic Function

• Autonomic Symptom Profile (ASP): Comprehensive autonomic assessment
• Orthostatic Blood Pressure Measurement: Autonomic failure quantification
• Urinary function assessment: Voiding diaries

Psychiatric Assessments

• Beck Depression Inventory (BDI): Depression
• Hamilton Anxiety Rating Scale: Anxiety
• Neuropsychiatric Inventory (NPI): Behavioral symptoms

Digital Biomarkers

Wearable Sensor Technology

Advances in wearable technology enable continuous monitoring of motor symptoms:

Gait Analysis

• Instrumented walkway systems: Spatial-temporal gait parameters
• Wearable inertial sensors: Step detection, gait variability
• Turn characteristics: Turning duration, number of steps
• Freezing of gait detection: Accelerometer-based algorithms

Movement Analysis

• Bradykinesia quantification: Finger tapping, hand movements
• Tremor analysis: Frequency, amplitude characterization
• Axial movements: Postural transitions, sit-to-stand

Eye Tracking

• Saccadic velocity: Vertical saccades specifically slowed in PSP
• Square wave jerks: Characteristic of PSP
• Anti-saccades: Impaired in PSP and CBS
• Fixation stability: Abnormal in PSP

Voice Analysis

• Acoustic analysis: Voice quality, pitch variation
• Speech rate: Reduced in parkinsonian syndromes
• Voice breaks: Characteristic dysarthria patterns

Smartphone Applications

• Finger tapping apps: Quantitative bradykinesia assessment
• Gait apps: Smartphone-based gait analysis
• Voice recording apps: Speech monitoring

Relevance to PSP

PSP biomarkers are critical for multiple clinical and research applications:

Clinical Applications

• MRI changes detectable 2-3 years before clinical diagnosis
• Blood NfL may serve as screening marker
• DAT imaging can support early differential diagnosis

• Imaging biomarkers provide key distinguishing features
• Fluid biomarkers for synucleinopathies vs. tauopathies
• Clinical phenotypic algorithms

• Annual MRI to document atrophy progression
• NfL levels correlate with clinical decline
• Clinical rating scales for symptom tracking

• Biomarker-positive patients for targeted trials
• Disease stage stratification
• Predictors of rapid vs. slow progression

Research Applications

• Pathophysiological insights: Understanding disease mechanisms
• Therapeutic target identification: Biomarker-driven drug development
• Patient stratification: Personalized medicine approaches
• Pharmacodynamic markers: Treatment response monitoring

Expected Outcomes

The comprehensive biomarker data from this study will enable:

• Validated biomarker panels for parkinsonian syndrome diagnosis
• Longitudinal biomarker trajectories showing changes over time
• Clinical validation of emerging biomarker candidates
• Foundation for future therapeutic trials with biomarker-driven enrollment

Current Biomarker Approaches in PSP

Summary of Biomarker Landscape

| Modality | Biomarker | Status | Utility |
|-------------|---------------|-----------|-------------|
| MRI | Midbrain atrophy | Validated | High |
| MRI | SCP atrophy | Validated | High |
| PET | Tau PET | Research | Moderate |
| DAT SPECT | Dopamine imaging | Validated | High |
| CSF | NfL | Clinical | Moderate |
| CSF | Alpha-synuclein SAA | Research | High |
| Blood | NfL | Research | Moderate |

Biomarker Integration Approaches

• Multimodal biomarker panels: Combining imaging, fluid, and clinical data
• Machine learning models: Integration for diagnostic classification
• Longitudinal tracking: Changes over time as progression markers

Future Directions

Emerging Biomarkers

• Tau isoform-specific assays: Distinguishing 3R vs. 4R tau
• MicroRNA signatures: Blood-based diagnostic panels
• Gut microbiome markers: Peripheral biomarkers linked to CNS pathology
• Olfactory testing: Non-invasive screening tool

Precision Medicine Applications

• Genotype-phenotype correlation: Genetic modifiers of biomarker expression
• Treatment response prediction: Biomarkers predictive of therapeutic benefit
• Individualized prognosis: Risk stratification models

Related Pages

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tauopathies](/diseases/tauopathies)
• [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
• [Tau PET Imaging](/diagnostics/tau-pet-imaging)
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)

External Links

• [ClinicalTrials.gov - NCT06501469](https://clinicaltrials.gov/study/NCT06501469)
• [MDS Criteria for PSP](https://www.ncbi.nlm.nih.gov/)
• [Armstrong et al. CBD Criteria](https://www.ncbi.nlm.nih.gov/)
• [Wenning et al. MSA Criteria](https://www.ncbi.nlm.nih.gov/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Multi-Modal Stress Response Harmonization](/hypothesis/h-1e564178) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: NR3C1/CRH/TNFA
• [Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: CLOCK/ULK1
• [Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PPARGC1A/PRKAA1
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Retinal Vascular Microcirculation Rescue](/hypothesis/h-35f04e1b) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: PDGFRB/ANGPT1
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Ocular Immune Privilege Extension](/hypothesis/h-6a065252) — <span style="color:#ffd54f;font-weight:600">0.43</span> · Target: FOXP3/TGFB1

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) &#x1f504;